New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTPG, PSX, MYL, CME, ACAT, OI, HBAN, AB, LAZ, TGT, STEL, EXPEOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AllianceBernstein (AB) upgraded to Equal Weight from Underweight at Morgan Stanley... CME Group (CME) upgraded to Outperform from Market Perform at Raymond James... Expedia (EXPE) upgraded to Buy from Hold at Benchmark Co.... Expedia (EXPE) upgraded to Outperform from Market Perform at Raymond James... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Citigroup... Mylan (MYL) upgraded to Buy from Hold at Canaccord... StellarOne (STEL) upgraded to Strong Buy from Outperform at Raymond James... Owens-Illinois (OI) upgraded to Buy from Neutral at BofA/Merrill... Phillips 66 (PSX) upgraded to Outperform from Neutral at Credit Suisse... Target (TGT) upgraded to Buy from Neutral at Buckingham... Arctic Cat (ACAT) upgraded to Strong Buy from Buy at Felti... Proctor and Gamble (PG) upgraded to Outperform from Underperform at CLSA... Lazard (LAZ) upgraded to Neutral from Sell at Rochdale.
News For AB;CME;EXPE;HBAN;MYL;STEL;OI;PSX;TGT;ACAT;PG;LAZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
August 28, 2015
07:22 EDTMYLMylan shareholders approve proposed acquisition of Perrigo
Subscribe for More Information
06:48 EDTHBANHuntington Bancshares upgraded to Buy from Neutral at Guggenheim
Subscribe for More Information
August 26, 2015
16:26 EDTLAZOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
13:40 EDTLAZPeabody hires Lazard to help with debt restructuring, Bloomberg reports
Peabody Energy (BTU) has hired Lazard (LAZ) to advise it on how to restructure its $6.3B of debt, Bloomberg reports, citing two people with knowledge of the matter. Peabody is having discussions with creditors over ways to reduce its debt load, including swapping obligations for new shares or convertible notes, the report says. Reference Link
10:07 EDTMYLMylan initiated with a Buy at Standpoint Research
Subscribe for More Information
06:55 EDTMYLMylan shares may sell off on affirmative Perrigo deal vote, says BMO Capital
With Mylan (MYL) set to hold a shareholder vote on August 28 regarding its proposed acquisition of Perrigo (PRGO), BMO Capital analyst David Maris predicts that if the vote goes in Mylan's favor, he expects Perrigo shares to rise and Mylan shares to fall. Afterward, he feels added overhangs, such as Teva's (TEVA) and Abbott's (ABT) shareholdings and potential short-term selling by arbitrageurs, will come into play, further pressuring Mylan shares.
05:58 EDTMYLPerrigo CEO says company is 'very active in M&A,' Bloomberg reports
Subscribe for More Information
August 25, 2015
16:01 EDTTGTTarget sees $550M pretax gain after closing CVS transaction
Subscribe for More Information
15:02 EDTMYLMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMYLTeva Copaxone patents to be reconsidered by regulators, Bloomberg says
14:16 EDTMYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTMYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTMYLTeva to refrain from voting at Mylan special meeting
Subscribe for More Information
11:23 EDTEXPEAnalyst says Priceline undervalued, looks poised to outperform
Subscribe for More Information
08:47 EDTPGKellogg names Carolyn Tastad to board of directors
Subscribe for More Information
08:04 EDTCMECME Group management to meet with Jefferies
Meetings to be held in Chicago/Santa Fe September 1-2 hosted by Jefferies.
August 24, 2015
15:01 EDTTGTWyndham slips after FTC given go-ahead for data breach lawsuit
Shares of Wyndham (WYN) have slipped in afternoon trading after an appeals court ruled that the FTC can sue the company over its allegedly poor cybersecurity practices. WHAT'S NEW: According to a Reuters report of court proceedings, the 3rd U.S. Circuit Court of Appeals in Philadelphia has ruled that the FTC may proceed with its lawsuit against Wyndham over data breaches in 2008 and 2009, saying the hotel company failed to take reasonable steps to protect customer information. Wyndham's allegedly lackluster data protection policies constitute "unfair and deceptive trade practices," granting the Federal Trade Commission authority to step in, said Judge Thomas Ambro. FTC Chairwoman Edith Ramirez commented, "It is not only appropriate, but critical, that the FTC has the ability to take action on behalf of consumers when companies fail to take reasonable steps to secure sensitive consumer information," according to the report. WHAT'S NOTABLE: Today's ruling comes in the wake of numerous high-profile "hack attacks," with American Airlines (AAL), Anthem (ANTM), United Airlines (UAL) and Target (TGT) all reporting digital security breaches in recent years. Though no final verdict has been reached in the case between the FTC and Wyndham, Judge Ambro may have established the beginnings of a legal precedent potentially allowing the Commission to sue companies for not going far enough to protect consumer data and Chairwoman Ramirez appeared to share that broader tone. PRICE ACTION: Shares of Wyndham are down about 4% in intraday trading. Cybersecurity firms FireEye (FEYE) and Palo Alto Networks (PANW) are down roughly 2% and 2.7% for the afternoon.
13:17 EDTTGTTarget to pay $2.8M to resolve EEOC discrimination finding
Target has agreed to pay $2.8M to resolve a Commissioner's charge of discrimination which was investigated in the Minneapolis Area Office of the U.S. Equal Employment Opportunity Commission, or EEOC. Based on the investigation, EEOC found reasonable cause to believe that three employment assessments formerly used by Target disproportionately screened out applicants for exempt-level professional positions based on race and sex. The tests were not sufficiently job-related and consistent with business necessity, and thus violated Title VII of the Civil Rights Act of 1964, EEOC found. In addition, EEOC found that one of the assessments Target formerly used in its hiring process also violated the Americans with Disabilities Act. The EEOC determined that this particular assessment performed by psychologists on behalf of Target was a pre-employment medical examination. Employers are prohibited by the ADA from subjecting applicants to medical examinations prior to an offer of employment. EEOC found that Target also committed record-keeping violations by failing to maintain records sufficient to assess the impact of its hiring procedures. EEOC's investigation revealed that thousands were adversely affected when Target used these assessments in its hiring process. The monetary settlement will be divided among these individuals as appropriate. Target will pay for a claims administrator to distribute the funds.
August 21, 2015
15:22 EDTMYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTMYLMylan to host special shareholder meeting
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use